Perrigo Company (NYSE:PRGO) Shares Sold by Financial Engines Advisors L.L.C.
Financial Engines Advisors L.L.C. reduced its position in shares of Perrigo Company (NYSE:PRGO) by 26.8% during the second quarter, Holdings Channel reports. The firm owned 2,777 shares of the company’s stock after selling 1,017 shares during the period. Financial Engines Advisors L.L.C.’s holdings in Perrigo were worth $210,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Moon Capital Management LLC boosted its position in shares of Perrigo by 0.6% in the first quarter. Moon Capital Management LLC now owns 43,265 shares of the company’s stock worth $2,872,000 after buying an additional 240 shares during the period. Credit Suisse AG boosted its position in shares of Perrigo by 13.8% in the first quarter. Credit Suisse AG now owns 241,688 shares of the company’s stock worth $16,046,000 after buying an additional 29,375 shares during the period. State of New Jersey Common Pension Fund D bought a new position in shares of Perrigo during the first quarter worth about $29,876,000. UBS Asset Management Americas Inc. boosted its position in shares of Perrigo by 2.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 339,902 shares of the company’s stock worth $28,289,000 after buying an additional 9,617 shares during the period. Finally, Amalgamated Bank boosted its position in shares of Perrigo by 6.0% in the first quarter. Amalgamated Bank now owns 9,759 shares of the company’s stock worth $648,000 after buying an additional 555 shares during the period. 76.38% of the stock is owned by institutional investors.
Shares of Perrigo Company (NYSE:PRGO) opened at 76.84 on Friday. Perrigo Company has a 12 month low of $63.68 and a 12 month high of $99.14. The firm’s market cap is $11.02 billion. The company’s 50-day moving average is $73.48 and its 200-day moving average is $73.02.
Perrigo (NYSE:PRGO) last released its earnings results on Thursday, August 10th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.28. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.18 billion. Perrigo had a negative net margin of 43.81% and a positive return on equity of 11.79%. The firm’s quarterly revenue was down 7.7% compared to the same quarter last year. During the same period last year, the firm posted $1.93 earnings per share. On average, equities research analysts forecast that Perrigo Company will post $4.32 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Friday, August 25th will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Wednesday, August 23rd. Perrigo’s dividend payout ratio (DPR) is currently -3.90%.
PRGO has been the subject of a number of research analyst reports. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $67.00 target price on shares of Perrigo in a report on Friday, April 14th. Deutsche Bank AG lowered their price target on shares of Perrigo from $87.00 to $86.00 and set a “buy” rating on the stock in a research report on Wednesday, April 19th. B. Riley reiterated a “neutral” rating and issued a $67.00 price target on shares of Perrigo in a research report on Saturday, April 22nd. Jefferies Group LLC reiterated a “hold” rating and issued a $71.00 price target on shares of Perrigo in a research report on Wednesday, May 24th. Finally, Canaccord Genuity set a $86.00 price target on shares of Perrigo and gave the company a “buy” rating in a research report on Monday, May 22nd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. Perrigo presently has a consensus rating of “Hold” and an average price target of $85.14.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Want to see what other hedge funds are holding PRGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Perrigo Company (NYSE:PRGO).
Receive News & Ratings for Perrigo Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Company and related companies with Analyst Ratings Network's FREE daily email newsletter.